Immunohistochemistry (IHC) Market Worth $3.3 Billion by 2026 - Global Trend, Business Analysis, Recent Development, Share Analysis
In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK’s anti-PD1 immunotherapy, JEMPERLI.
View full press release